Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
BACKGROUND
In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19.


METHODS
We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days). Outcomes were death, clinical worsening (transfer to ICU, and >10 day hospitalization) and viral shedding persistence (>10 days).


RESULTS
A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years - range 14-95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74-95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision).


CONCLUSION
Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients.
['Million|Matthieu|M|', 'Lagier|Jean-Christophe|JC|', 'Gautret|Philippe|P|', 'Colson|Philippe|P|', 'Fournier|Pierre-Edouard|PE|', 'Amrane|Sophie|S|', 'Hocquart|Marie|M|', 'Mailhe|Morgane|M|', 'Esteves-Vieira|Vera|V|', 'Doudier|Barbara|B|', 'Aubry|Camille|C|', 'Correard|Florian|F|', 'Giraud-Gatineau|Audrey|A|', 'Roussel|Yanis|Y|', 'Berenger|Cyril|C|', 'Cassir|Nadim|N|', 'Seng|Piseth|P|', 'Zandotti|Christine|C|', 'Dhiver|Catherine|C|', 'Ravaux|Isabelle|I|', 'Tomei|Christelle|C|', 'Eldin|Carole|C|', 'Tissot-Dupont|Hervé|H|', 'Honoré|Stéphane|S|', 'Stein|Andreas|A|', 'Jacquier|Alexis|A|', 'Deharo|Jean-Claude|JC|', 'Chabrière|Eric|E|', 'Levasseur|Anthony|A|', 'Fenollar|Florence|F|', 'Rolain|Jean-Marc|JM|', 'Obadia|Yolande|Y|', 'Brouqui|Philippe|P|', 'Drancourt|Michel|M|', 'La Scola|Bernard|B|', 'Parola|Philippe|P|', 'Raoult|Didier|D|']
D000293:Adolescent D000328:Adult D000368:Aged D000369:Aged, 80 and over D000998:Antiviral Agents D017963:Azithromycin D000073640:Betacoronavirus D000086382:COVID-19 D018352:Coronavirus Infections D004359:Drug Therapy, Combination D005260:Female D005500:Follow-Up Studies D005602:France D006801:Humans D006886:Hydroxychloroquine D008297:Male D008875:Middle Aged D058873:Pandemics D011024:Pneumonia, Viral D016133:Polymerase Chain Reaction D012189:Retrospective Studies D000086402:SARS-CoV-2 D013997:Time Factors D016896:Treatment Outcome D019562:Viral Load D055815:Young Adult
COVID-19 Hydroxychloroquine Azithromycin SARS-CoV-2